A Phase 1/2 study of ATV-1601 in hereditary hemorrhagic telangiectasia (HHT)

Study Description

A study testing an investigational oral medication (ATV-1601) to treat moderate to severe hereditary hemorrhagic telangiectasia, a condition that causes abnormal blood vessel formation and bleeding

Study Details

Registry ID:

NCT07601425

Conditions:

Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease

Phase:

Phase 1,Phase 2

Target Enrollment:

100 participants

Start Date:

July 27, 2026

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Massachusetts General Hospital
  Boston, MassachusettsUnited States, United States
• Mayo Clinic
  Rochester, MinnesotaUnited States, United States
• Barrow Neurological Institute
  Phoenix, ArizonaUnited States, United States
• Arizona Pulmonary Specialists
  Phoenix, ArizonaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →